FDA Approves BIKTARVY — Gilead Sciences, Inc.

Gilead Sciences, Inc. announced the approval of BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate), a fully-supply single-tablet regimen that significantly broadens treatment options for HIV-1 patients and bolsters the company’s dominant position in the global antiretroviral market. The new formulation is expected to drive considerable uptake in both the domestic and international markets by offering enhanced convenience and pharmacokinetic profiles compared to previous combination therapies.